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ABSTRACT 
4-Bromomethylcoumarins (1a-k) were reacted with 3-hydroxypyridines (2a-b) to yield 
pyridinoxymethylcoumarins (3a-r). The structure of all the synthesized compounds were 
confirmed by spectral studies and screened for their cytotoxic activities against Dalton’s Ascitic 
Lymphoma (DAL) and Ehrlich Ascites Carcinoma (EAC) cell lines.  Out of these, the compound (3o) 
was found to be the most cytotoxic against DAL cell line and the compound (3m) was found to be 
the most cytotoxic against EAC cell line. 
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1. INTRODUCTION  
Pyridine derivatives are found to exhibit a 
wide spectrum of biological activities [1]. 2-
Chloropyridine derivatives containing flavone 
moiety strongly inhibited telomerase with IC50 
value of 0.8±0.07μm by a modified TRAP assay [2]. 
2-Amino-4-methyl-5-
phenylsulfonylmethylpyridine exhibited potent 
fungicidal activity against Alternaria tennis [3]. 
Triazolyl pyridines were found to be potential 
focal adhesion kinase (FAK) inhibitor as 
antitumour agents against HCT116 cell lines with 
IC50 values of 8.17μm [4]. 2,4,6-Triarylpyridines 
showed stronger topo ΙΙ inhibitory activity than 
etoposide [5]. Benzimidazoyl and benzthiazolyl 
pyridines displayed the most pronounced activity 
against Melanoma cancer as MDA-MB-435 cell 
lines [6]. Pyridine derivatives inhibited kinase 
CDK5 with an inhibitory concentration of 160nM 
[7]. Molecular iodine catalysed, one pot synthesis of 
pyridine ring fused with imidazo ring has been 
reported [8]. 
Coumarins constitute an important class 
of benzopyrones exhibiting a broad range of 
biological activities [9].  One pot conversion of 
aminocoumarins to coumarinyl isothiocyanate 
with excellent yield has been described [10].  
Synthesis of coumarins via Pechmann cyclisation 
using poly(4-vinylpyridine)-supported sulfuric 
acid as a reusable catalyst has been reported [11].  
Quinoxalylcoumarins were synthesised from 
bromoacetyl coumarins under microwave 
irradiation [12]. Six new 4-hydroxycoumarin 
derivatives were synthesized and studied by 
computational methods-DFT (B3LYP) and force 
field methods (MM2 and OPLS), in order to 
optimize their geometry and calculate quantum-
chemical properties and conformational analysis 
[13].  The molecular and crystal structure of 8-
acetyl-7-[2-(1-morpholino)ethoxyl]-4-
ethylchromen-2-one in solid state were analyzed 
by X-ray diffraction. The compound crystallized in 
the monoclinic space group P21/c [14]. 
Phosphorohydrazine derivatives of coumarin 
demonstrated high in vivo antitumour activity 
against P388 leukemia [15].  Coumarin pyrazoline 
hybrids possessed the highest cytotoxicity against 
colorectal cell line HCT-116 with IC50 value of 
0.01μM [16]. Thiazolyl coumarin derivatives 
showed significant inhibition against Haemphilus 
influenzae with a MIC value of 15μM less than that 
of tetracycline [17]. Based on these reports, we 
considered the possibility of introducing pyridine 
moiety into the coumarin unit to design novel 
structures with enhanced cytotoxic activities. 
1.1. Chemistry 
4-Bromomethylcoumarins (1a-k) [18, 19] 
were synthesized by the Pechmann cyclisation of 
phenols with 4-bromoethylacetoacetate [20]. 
Various 4-bromomethylcoumarins (1a-k) reacted 
with 3-hydroxypyridines (2a-b) in the presence of 
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anhydrous K2CO3 to give 4-(pyridin-3-
yloxymethyl)-2H-chromen-2-ones (3a-r) (Scheme 
1). The numbering of the skeleton (3m) is shown 
in Figure 1. 
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Scheme - 1: Synthesis of the 
pyridinoxymethylcoumarins 
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Figure - 1: Numbering of the compound (3m) 
2. METHODS AND MATERIALS 
2.1. MATERIALS  
 The melting points were determined by 
open capillary method using electric melting point 
apparatus and are uncorrected. The IR spectra 
(KBr disc) were recorded on a Shimadzu-8400S 
FT-IR Spectrophotometer. 1H NMR, 13C NMR and 
HSQC were recorded on Bruker 400MHz 
spectrometer by using CDCl3 and DMSO-d6 as a 
solvent and TMS as an internal standard. The 
chemical shifts are expressed in δ ppm. Elemental 
analyses (C, H, N) were conducted using the 
Elemental Analyser XBO. The mass spectra were 
recorded using Agilent-Single Quartz LC-MS. The 
purity of the compound was checked by TLC. 
2.2. General procedure for synthesis of 
pyridinoxymethylcoumarins (3a-r) 
 A mixture of 3-hydroxypyridine (2a-b) 
(3.4 mmol) and anhydrous K2CO3 (1.38 g, 10 
mmol) were stirred in 25mL of dry acetone for 30 
min. 4-Bromomethylcoumarin (1a-k) (3.4 mmol) 
was added and stirring was continued for 24 h. 
The reaction mixture was concentrated to one 
fourth volume and poured on to crushed ice. The 
solid separated was filtered and washed with 
water. The crude product was dried and 
recrystalized from ethanol.   
2.2.1. 6-Methyl-4-((2-amino-pyridin-3-yloxy) 
methyl)-2H-chromen-2-one (3a) 
Yield 95%; colorless solid; m.p.: 233-235 
°C; IR (KBr): 1706 cm‾1 (lactone C = O), 3145 cm‾1, 
3099 cm‾1; 1H NMR (400 MHz, DMSO-d6): δ = 2.49 
(s, 3H, C6-CH3), 5.38 (s, 2H, OCH2), 5.95 (s, 2H, 
NH2), 6.52 (t, 1H, C17-H, J1,2 = 5.2 Hz), 6.91 (s, 1H, 
C3-H), 7.33-7.35 (m, 2H, C8-H and C5-H), 7.46 (d, 
1H, C7-H, J1,2 = 8.8 Hz), 7.56 (d, 1H, C18-H, J1,2 = 4.8 
Hz), 7.73 (s, 1H, C16-H) ppm; Anal. Calcd for 
C16H14N2O3: C, 68.08: H, 5.0: N, 9.92. Found: C, 
67.98: H, 4.97: N, 9.80. 
2.2.2. 7-Methyl-4-((2-amino-pyridin-3-yloxy) 
methyl)-2H-chromen-2-one (3b) 
 Yield 92%; colorless solid; m.p.: 221-223 
°C; IR (KBr): 1726 cm‾1 (lactone C = O), 3139 cm‾1, 
3074 cm‾1; 1H NMR (400 MHz, DMSO-d6): δ = 2.48 
(s, 3H, C7-CH3), 5.36 (s, 2H, OCH2),  5.86 (s, 2H, 
NH2), 6.50 (t, 1H, C17-H, J1,2 = 5.2 Hz), 6.80 (s, 1H, 
C3-H), 7.20 (d, 1H, C5-H,  J 1,2 = 7.2 Hz), 7.26 (s, 1H, 
C8-H), 7.29 (d, 1H, C6-H, J1,2 = 6.8 Hz), 7.55 (d, 1H, 
C18-H, J1,2 = 6 Hz), 7.76 (d, 1H,  C16-H, J1,2 = 8 Hz) 
ppm; Anal. Calcd for C16H14N2O3: C, 68.08: H, 5.0: 
N, 9.92. Found: C, 67.99: H, 4.96: N, 9.81. 
2.2.3. 6-Methoxy-4-((2-amino-pyridin-3-yloxy) 
methyl)-2H-chromen-2-one (3c) 
Yield 90%; colorless solid; m.p.: 195-197 
°C; IR (KBr): 1722 cm‾1 (lactone C = O), 3149 cm‾1; 
1H NMR (400 MHz, CDCl3): δ = 3.84 (s, 3H, OCH3), 
4.72 (s, 2H, NH2, D2O exchangeable), 5.21 (s, 2H, 
OCH2), 6.59 (s, 1H, C3-H), 6.62 (t, 1H, C17-H, J1,2 = 
5.2 Hz), 6.97-7.00 (m, 2H, C5-H & C18-H), 7.14 (d, 
1H, C7-H, J1,2 = 6.4 Hz), 7.32 (d, 1H, C8-H, J1,2 = 9.2 
Hz), 7.74 (d, 1H, C16-H, J1,2 = 4.8 Hz)  ppm; Anal. 
Calcd for C16H14N2O4: C, 64.42: H, 4.73: N, 9.39. 
Found: C, 64.03: H, 4.55: N, 9.23. 
2.2.4. 6-Ethyl-4-((2-amino-pyridin-3-yloxy) 
methyl)-2H-chromen-2-one (3d)   
Yield 95%; colorless solid; m.p.: 194-196 
°C; IR (KBr): 1706 cm‾1 (lactone C = O), 3161 cm‾1, 
3066 cm‾1; 1H NMR (400 MHz, CDCl3): δ = 1.27 (t, 
3H, CH3 of C2H5, J1,2 = 7.6Hz), 2.71 (q, 2H, CH2 of 
C2H5), 4.71 (s, 2H, NH2), 5.25 (s, 2H, OCH2), 6.58 (s, 
1H, C3-H), 6.62 (t, 1H, C17-H, J1,2 = 4.8 Hz), 7.00 (d, 
1H ,C18-H, J1,2 = 6.8 Hz), 7.31 (s, 1H, C5-H), 7.34 (d, 
1H, C8-H, J1,2 = 4.4 Hz), 7.41 (d, 1H, C7-H, J1,2 = 6.4 
Hz), 7.75 (d, 1H, C16-H, J1,2 = 6 Hz) ppm; Anal. Calcd 
for C17H16N2O3: C, 68.91: H, 5.44: N, 9.45. Found: C, 
68.88: H, 5.21: N, 9.21. 
2.2.5. 6-Isopropyl-4-((2-amino-pyridin-3-
yloxy) methyl)-2H-chromen-2-one (3e) 
Yield 91%; colorless solid; m.p.: 194-196 
°C; IR (KBr, cm‾1): 1710 cm‾1 (lactone C = O), 3137 
cm‾1, 3058 cm‾1; 1H NMR (400 MHz, CDCl3): δ = 
1.27 (d, 6H, 2-CH3 of isopropyl, J1,2 = 6.8Hz), 2.95 
(m, 1H, CH of isopropyl, J1,2 = 7.2Hz), 4.71 (s, 2H, 
NH2, D2O exchangeable), 5.26 (s, 2H, OCH2), 6.58 
(s, 1H, C3-H), 6.63 (t, 1H, C17-H, J1,2 = 5.2 Hz), 7.01 
Research Paper                                                                                                           www.ijcps.com 
 
74 
 
(d, 1H, C18-H, J1,2 = 7.2 Hz), 7.33-7.35 (m, 2H, C5-H 
& C8-H), 7.45 (d, 1H, C7-H, J1,2 = 6.8 Hz), 7.75 (d, 1H, 
C16-H, J1,2 = 6 Hz) ppm; 13C NMR (400 MHz, CDCl3): 
δ = 24.55 (C21 and C20), 34.31 (C19),  66.42 (C11), 
114.07 (C3), 114.11 (C10), 117.26(C18), 117.92 (C8), 
121.14 (C17), 131.17 (C7), 140.89 (C5), 140.93 
(C16), 145.86 (C6), 149.71 (C9), 150.56 (C13 and 
C14), 152.50 (C4), 161.08 (C2) ppm; LC-MS: m/z = 
311(M+H); Anal. Calcd for C18H18N2O3: C, 69.66: H, 
5.85: N, 9.03. Found: C, 69.31: H, 5.60: N, 8.79. 
2.2.6. 6-tert-Butyl-4-((2-amino-pyridin-3-
yloxy) methyl)-2H-chromen-2-one (3f) 
Yield 91%; colorless solid; m.p.: 184-186 
°C; IR (KBr): 1697 cm‾1 (lactone C = O), 3143 cm‾1, 
3089 cm‾1; 1H NMR (400 MHz, CDCl3): δ = 1.35 (s, 
9H, 6-tert-butyl), 4.70 (s, 2H, NH2), 5.27 (s, 2H, 
OCH2), 6.58 (s, 1H, C3-H), 6.63 (t, 1H, C17-H, J1,2 = 
4.8 Hz), 7.01 (d, 1H, C18-H, J1,2 = 6.8 Hz), 7.33 (d, 
1H,  C8-H, J1,2 = 8.8 Hz), 7.48 (s, 1H, C5-H), 7.63 (d, 
1H, C7-H, J1,2 = 6.8 Hz), 7.75 (d, 1H, C16-H, J1,2 = 6.4 
Hz) ppm); Anal. Calcd for C19H20N2O3: C, 70.35: H, 
6.21: N, 8.64. Found: C, 70.11: H, 6.03: N, 8.32. 
2.2.7. 6-Benzyl-4-((2-amino-pyridin-3-yloxy) 
methyl)-2H-chromen-2-one (3g) 
Yield 95%; colorless solid; m.p.: 173-175 
°C; IR (KBr): 1701 cm‾1 (lactone C = O), 3338 cm‾1; 
1H NMR (400 MHz, CDCl3): δ = 4.04 (s, 2H, C6-CH2), 
4.63 (s, 2H, NH2), 5.19 (s, 2H, OCH2), 6.57 (s, 1H, 
C3-H), 6.62 (t, 1H, C17-H, J1,2 = 4.8  Hz), 6.96-7.76 
(m, 10H, Ar-H) ppm; Anal. Calcd for C22H18N2O3: C, 
73.73: H, 5.06: N, 7.82. Found: C, 73.21: H, 5.01: N, 
7.62. 
2.2.8. 1-((2-Amino-pyridin-3-yloxy) methyl)-
3H- benzo(f)chromen-3-one (3h)     
Yield 94%; colorless solid; m.p.: 228-230 
°C; IR (KBr): 1718 cm‾1 (lactone C = O), 3153 cm‾1, 
3074 cm‾1; 1H NMR (400 MHz, DMSO-d6): δ = 5.76 
(s, 2H, OCH2), 5.80 (s, 2H, NH2), 6.53 (t, 1H, C21-H, 
J1,2 = 4.8 Hz), 6.95 (s, 1H, C3-H), 7.28-8.33 (m, 8H, 
Ar-H) ppm; Anal. Calcd for C19H14N2O3: C, 71.69: H, 
4.43: N, 8.80. Found: C, 71.21: H, 4.34: N, 8.62. 
2.2.9. 6-Chloro-4-((2-amino-pyridin-3-yloxy) 
methyl)-2H-chromen-2-one (3i) 
Yield 92%; colorless solid; m.p.: 233-235 
°C; IR (KBr): 1699 cm‾1 (lactone C = O), 3105 cm‾1, 
3064 cm‾1; 1H NMR (400 MHz, DMSO-d6): δ = 5.36 
(s, 2H, OCH2), 5.92 (s, 2H, NH2), 6.50 (t, 1H, C17-H, 
J1,2 = 5.2 Hz), 7.0 (s, 1H, C3-H), 7.37 (d, 1H, C8-H, J1,2 
= 7.2 Hz), 7.47 (d, 1H, C18-H, J1,2 = 8.8 Hz), 7.55 (d, 
1H, C16-H, J1,2 = 4.4 Hz), 7.67 (d, 1H, C7-H, J1,2 = 4.4 
Hz), 8.01 (s, 1H, C5-H) ppm; Anal. Calcd for 
C15H11ClN2O3: C, 59.52: H, 3.66: N, 9.25. Found: C, 
59.21: H, 3.34: N, 9.09. 
2.2.10. 6-Bromo-4-((2-amino-pyridin-3-yloxy) 
methyl)-2H-chromen-2-one (3j) 
Yield 89%; colorless solid; m.p.: 231-233 
°C; IR (KBr): 1708 cm‾1 (lactone C = O), 3105 cm‾1, 
3060 cm‾1; 1H NMR (400 MHz, DMSO-d6): δ = 5.36 
(s, 2H, OCH2), 5.92 (s, 2H, NH2), 6.50 (t, 1H, C17-H, 
J1,2 = 4.8 Hz), 6.99 (s, 1H, C3-H), 7.38-7.40 (m, 2H, 
C18-H and C8-H), 7.55 (d, 1H, C16-H, J1,2 = 4.8 Hz), 
7.78 (d, 1H, C7-H, J1,2 = 6.8 Hz), 8.12 (s, 1H, C5-H) 
ppm; Anal. Calcd for C15H11BrN2O3: C, 51.90: H, 
3.19: N, 8.07. Found: C, 51.21: H, 3.11: N, 8.01. 
2.2.11. 6-Fluoro-4-((2-amino-pyridin-3-yloxy) 
methyl)-2H-chromen-2-one (3k) 
Yield 88%; colorless solid; m.p.: 230-232 
°C; IR (KBr): 1716 cm‾1 (lactone C = O), 3141 cm‾1, 
3070 cm‾1; 1H NMR (400 MHz, DMSO-d6): δ = 5.34 
(s, 2H, OCH2), 5.92 (s, 2H, NH2), 6.51 (t, 1H, C17-H, 
J1,2 = 5.2 Hz), 7.00 (s, 1H, C3-H), 7.35 (d, 1H, C17-H, 
J1,2 = 6.8 Hz), 7.49-7.55 (m, 3H, C5-H, C8-H, and C16-
H), 7.79 (d, 1H, C7-H, J1,2 = 6.8 Hz) ppm; Anal. Calcd 
for C15H11FN2O3: C, 62.94: H, 3.87: N, 9.79. Found: 
C, 62.69: H, 3.78: N, 9.71. 
2.2.12. 7-Methyl-4-((2-methyl-pyridin-3-yloxy) 
methyl)-2H-chromen-2-one (3l)  
Yield 86%; colorless solid; m.p.: 220-222 
°C; IR (KBr): 1701 cm‾1 (lactone C = O); 1H NMR 
(400 MHz, DMSO-d6): δ = 2.42 (s, 3H, C7-CH3), 2.49 
(s, 3H, C14-CH3), 5.44 (s, 2H, OCH2), 6.50 (s, 1H, C3-
H), 7.21-7.28 (m, 3H, C17-H, C18-H, and C8-H), 7.56 
(d, 1H, C6-H, J1,2 = 7.2 Hz), 7.76 (d, 1H, C5-H, J1,2 = 8 
Hz), 8.05 (d, 1H, C16-H, J1,2 = 5.6 Hz) ppm; Anal. 
Calcd for C17H15NO3: C, 72.58: H, 5.37: N, 4.98. 
Found: C, 72.22: H, 5.12: N, 4.60. 
2.2.13. 6-Isopropyl-4-((2-methyl-pyridin-3-
yloxy) methyl)-2H-chromen-2-one (3m) 
Yield 89%; colorless solid; m.p.: 160-162 
°C; IR (KBr): 1704 cm‾1 (lactone C = O); 1H NMR 
(400 MHz, DMSO-d6): δ = 1.24 (d, 6H, 2-CH3 of 
isopropyl, J1,2 = 7.2 Hz), 2.50 (s, 3H, C14-CH3), 3.01 
(m, 1H, CH of isopropyl, J1,2 = 7.2 Hz), 5.49 (s, 2H, 
OCH2), 6.57 (s, 1H, C3-H), 7.25 (t, 1H, C17-H, J1,2 = 
4.8 Hz), 7.38 (d, 1H, C18-H, J1,2 = 8.8 Hz), 7.56 (d, 
1H, C7-H, J1,2 = 6.4 Hz), 7.63 (d, 1H, C8-H, J1,2 = 7.6 
Hz), 7.71 (s, 1H, C5-H), 8.07 (d, 1H, C16-H, J1,2 = 6 
Hz) ppm; 13C NMR (400 MHz, CDCl3): δ = 20.09 
(C22), 24.55 (C21 and C20), 34.34 (C19), 65.99 (C11), 
113.93 (C3), 117.24 (C18), 117.90 (C10), 118.28 
(C8), 121.09 (C17), 122.23 (C5), 131.12 (C7), 142.21 
(C16), 145.80 (C6), 149.68 (C9), 149.85 (C13 and 
C14), 152.45 (C4), 161.16 (C2) ppm; Anal. Calcd for 
C19H19NO3: C, 73.77: H, 6.19: N, 4.53. Found: C, 
73.52: H, 6.02: N, 4.44. 
2.2.14. 6-tert-Butyl-4-((2-methyl-pyridin-3-
yloxy) methyl)-2H-chromen-2-one (3n) 
Yield 90%; colorless solid; m.p.: 136-137 
°C; IR (KBr): 1706 cm‾1 (lactone C = O); 1H NMR 
(400 MHz, CDCl3): δ = 1.36 (s, 9H, 6-tert-butyl), 
2.56 (s, 3H, C14-CH3), 5.28 (s, 2H, OCH2), 6.64 (s, 
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1H, C3-H), 7.13-7.19 (m, 2H, C17-H and C18-H), 7.33 
(d, 1H, C8-H, J1,2 = 8.8 Hz), 7.50 (s, 1H, C5-H), 7.62 
(d, 1H, C7-H, J1,2 = 6.4 Hz), 8.17 (d, 1H, C16-H, J1,2 = 
5.6 Hz) ppm; Anal. Calcd for C20H21NO3: C, 74.28: 
H, 6.55: N, 4.33. Found: C, 74.11: H, 6.43: N, 4.23. 
2.2.15. 1-((2-Methyl-pyridin-3-yloxy) methyl)-
3H- benzo (f) chromen-3-one (3o) 
Yield 89%; colorless solid; m.p.: 222-224 
°C; IR (KBr): 1706 cm‾1 (lactone C = O); 1H NMR 
(400 MHz, DMSO-d6): δ = 2.38 (s, 3H, C18-CH3), 
5.83 (s, 2H, OCH2), 6.81 (s, 1H, C3-H), 7.24 (t, 1H, 
C21-H, J1,2 = 4.8 Hz), 7.60-8.32 (m, 8H, Ar-H) ppm; 
Anal. Calcd for C20H15NO3: C, 75.70: H, 4.76: N, 
4.41. Found: C, 75.31: H, 4.43: N, 4.23. 
2.2.16. 6-Chloro-4-((2-methyl-pyridin-3-yloxy) 
methyl)-2H-chromen-2-one (3p) 
 Yield 94%; colorless solid; m.p.: 226-228 
°C; IR (KBr): 1706 cm‾1 (lactone C = O); 1H NMR 
(400 MHz, DMSO-d6): δ = 2.46 (s, 3H, C14-CH3), 
5.46 (s, 2H, OCH2), 6.62 (s, 1H, C3-H), 7.23 (t, 1H, 
C17-H, J1,2 = 4.8 Hz), 7.49 (d, 1H, C18-H, J1,2 = 8.8 Hz), 
7.63 (d, 1H, C8-H, J1,2 = 7.6 Hz), 7.70 (d, 1H, C7-H, J1,2 
= 6.4 Hz), 8.01 (s, 1H, C5-H), 8.06 (d, 1H, C16-H, J1,2 
=  4.8 Hz) ppm; Anal. Calcd for C16H12ClNO3: C, 
63.69: H, 4.01: N, 4.64. Found: C, 63.21: H, 3.98: N, 
4.39. 
2.2.17. 6-Bromo-4-((2-methyl-pyridin-3-yloxy) 
methyl)-2H-chromen-2-one (3q) 
Yield 93%; colorless solid; m.p.: 234-236 
°C; IR (KBr): 1710 cm‾1 (lactone C = O); 1H NMR 
(400 MHz, DMSO-d6): δ = 2.46 (s, 3H, C14-CH3), 
5.46 (s, 2H, OCH2), 6.61 (s, 1H, C3-H), 7.22 (t, 1H, 
C17-H, J1,2 = 4.8 Hz), 7.42 (d, 1H, C18-H, J1,2 = 8.8 Hz), 
7.63 (d, 1H, C8-H, J1,2 = 7.6 Hz), 7.81 (d, 1H, C7-H, J1,2 
= 6.4 Hz), 8.06 (d, 1H, C16-H, J1,2 = 4.8 Hz), 8.13 (s, 
1H, C5-H) ppm; Anal. Calcd for C16H12BrNO3: C, 
55.51: H, 3.49: N, 4.05. Found: C, 55.21: H, 3.33: N, 
4.01. 
2.2.18. 6-Fluoro-4-((2-methyl-pyridin-3-yloxy) 
methyl)-2H-chromen-2-one (3r) 
Yield 95%; colorless solid; m.p.:233-235 
°C; IR (KBr); 1701 cm‾1 (lactone C = O); 1H NMR 
(400 MHz, DMSO-d6): δ = 2.46 (s, 3H, C14-CH3), 
5.43 (s, 2H, OCH2), 6.62 (s, 1H, C3-H), 7.23 (t, 1H, 
C17-H, J1,2 = 4.8 Hz), 7.51-7.56 (m, 2H, C18-H and C5-
H), 7.60 (d, 1H, C8-H, J1,2 = 7.6 Hz), 7.77 (d, 1H, C7-
H, J1,2 = 6.8 Hz), 8.06 (d, 1H, C16-H, J1,2 = 5.6 Hz) 
ppm; Anal. Calcd for C16H12FNO3: C, 67.37: H, 4.24: 
N, 4.91. Found: C, 67.21: H, 4.11: N, 4.87. 
3. RESULTS AND DISCUSSION 
The structures of novel 
pyridinoxymethylcoumarins were established 
from IR, 1H NMR, 13C NMR and LC-MS data as 
illustrated for a representative example. In the IR 
spectrum of 6-isopropyl-4-((2-amino-pyridin-3-
yloxy)methyl)-2H-chromen-2-one (3e) [R1 = 6-i-
Pr, R2 = NH2], the lactone carbonyl stretching 
frequency was appeared at 1710 cm−1, where as 
NH2 stretching frequency was appeared at 3137 
cm−1 and 3058 cm−1.  The 1H NMR spectrum of the 
compound (3e) displayed a singlet at δ 4.71, 5.26 
and 6.58 due to NH2 (D2O exchangeable), OCH2 
and C3-H respectively.  A multiplet was observed 
at δ 2.95 (J1,2 = 7.2 Hz) due to methine proton of 
isopropyl group.  The two methyl group of 
isopropyl, C18-H, C7-H and C16-H protons were 
resonated as a doublet at δ 1.27 (J1,2 = 6.8 Hz), 7.01 
(J1,2 = 7.2 Hz), 7.45 (J1,2 = 6.8 Hz), and 7.75 (J1,2 = 6 
Hz)  respectively.  The C5-H and C8-H protons 
appeared as a multiplet in the range of δ 7.33-7.35 
and C17-H proton as a triplet at δ 6.63 (J1,2 = 5.2 
Hz). 
The mass spectrum (LC-MS) of the 
compound (3e) exhibited a [M+H] peak at 311, 
which is in agreement with the molecular formula 
C18H18N2O3. The 13C NMR spectral data of 
compound (3e) (R1 = 6-iso-Pr, R2 = NH2) and (3m) 
(R1 = 6-iso-Pr, R2 = CH3) are given in experimental 
section, which are confirmed by their HSQC 
spectrum. 
3.1. Biological activity 
3.1. 2. In vitro cytotoxic screening 
The newly synthesized compounds were 
evaluated for their in vitro cytotoxic activity 
against Dalton’s Ascites Lymphoma (DAL) and 
Ehrlich Ascites Carcinoma (EAC) cells. 5-
Fluorouracil was used as the reference drug in this 
study. 
The relationship between surviving 
fraction and drug concentration was plotted to 
obtain the survival curve of Dalton’s Ascites 
Lymphoma (DAL) and Ehrlich Ascites Carcinoma 
(EAC) cells. The response parameter calculated 
was the IC50 value, which corresponds to the 
concentration required for 50% inhibition of cell 
viability. 
The IC50 of the synthesized compounds 
compared to the reference drug are shown in 
Table 1 and the results are represented 
graphically in Figure 2. 
The investigation of in vitro cell cytotoxicity 
against DAL cell revealed that the most of the 
tested compounds exhibited good activity. The 
compound (3o) (R1 = 5,6-Benzo, R2 = CH3) was the 
most potent cytotoxic compound in this screening 
against DAL cell with IC50 value of 30.21µg/mL. 
The compounds (3b) (R1 = 7-CH3, R2 = NH2), (3m) 
(R1 = 6-i-Pr, R2 = CH3), (3p) (R1 = 6-Cl,  
R2 = CH3), (3q) (R1 = 6-Br, R2 = CH3) and 
(3r) (R1 = 6-F, R2 = CH3) were found to be highly 
Research Paper                                                                                                           www.ijcps.com 
 
76 
 
Table - 1: Results of in vitro cytotoxic activity of the synthesized compounds on DAL and 
EAC cells 
Compounds R1 R2 DAL IC50 EAC IC50 
3a 6-CH3 NH2 86.41 56.26 
3b 7-CH3 NH2 68.74 51.20 
3c 6-OCH3 NH2 86.79 148.24 
3d 6-Et NH2 79.23 103.42 
3e 6-i-Pr NH2 80.20 155.24 
3f 6-tert-Butyl NH2 93.35 79.21 
3g 6-Benzyl NH2 94.60 87.24 
3h 5,6-Benzo NH2 85.22 135.21 
3i 6-Cl NH2 104.67 95.25 
3j 6-Br NH2 106.37 125.30 
3k 6-F NH2 78.24 109.27 
3l 7-CH3 CH3 86.07 57.21 
3m 6-i-Pr CH3 75.81 37.34 
3n 6-tert-Butyl CH3 87.51 99.12 
3o 5,6-Benzo CH3 30.21 150.38 
3p 6-Cl CH3 75.14 115.34 
3q 6-Br CH3 47.21 120.42 
3r 6-F CH3 64.97 117.28 
5-Fluorouracil   41.6 41.6 
 
 
Figure - 2: IC50 of the synthesized compounds compared to the reference drug 
active against DAL cells with IC50 value between 
47.21 and 75.81µg/mL. The compounds (3a) (R1 = 
6-CH3, R2 = NH2), (3c) (R1 = 6-OCH3, R2 = NH2), (3d) 
(R1 = 6-Et, R2 = NH2), (3e) (R1 = 6-i-Pr, R2 = NH2), 
(3h) (R1 = 5,6-Benzo, R2 = NH2), (3k) (R1 = 6-F, R2 = 
NH2), (3l) (R1 = 7-CH3, R2 = CH3) and (3n) (R1 = 6-
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tert-Butyl, R2 = CH3) showed moderate activity 
against DAL cell with IC50 value between 79.23 
and 87.51µg/mL. The compounds (3f) (R1 = 6-tert-
Butyl, R2 = NH2), (3g) (R1 = 6-Benzyl, R2 = NH2), 
(3i) (R1 = 6-Cl, R2 = NH2) and (3j) (R1 = 6-Br, R2 = 
NH2) showed poor activity against DAL cell with 
IC50 value between 93.35 and 106.37µg/mL. 
The investigation of in vitro cell 
cytotoxicity against EAC cell revealed that most of 
the tested compounds exhibited good activity. The 
compound (3m) (R1 = 6-i-Pr, R2 = CH3) was the 
most potent cytotoxic compound in this screening 
against EAC cell with IC50 value of 37.34µg/mL.  
The compounds (3a) (R1 = 6-CH3, R2 = NH2), (3b) 
(R1 = 7-CH3, R2 = NH2), (3f) (R1 = 6-tert-Butyl, R2 = 
NH2) and (3l) (R1 = 7-CH3, R2 = CH3) were found to 
be highly active against EAC cell with IC50 value 
between 51.20 and 79.21µg/mL. The compound 
(3g) (R1=6-Benzyl, R2=NH2) showed moderate 
activity against EAC cell with IC50 value of 
87.24µg/mL. The compounds (3c) (R1 = 6-OCH3, 
R2 = NH2), (3d) (R1 = 6-Et, R2 = NH2), (3e) (R1 = 6-i-
Pr, R2 = NH2), (3h) (R1 = 5,6-Benzo, R2 = NH2), (3i) 
(R1 = 6-Cl, R2 = NH2), (3j) (R1 = 6-Br, R2 = NH2), (3k) 
(R1 = 6-F, R2 = NH2), (3n) (R1 = 6-tert-Butyl, R2 = 
CH3), (3o) (R1 = 5,6-Benzo, R2 = CH3), (3p) (R1 = 6-
Cl, R2 = CH3), (3q) (R1 = 6-Br, R2 = CH3) and (3r) (R1 
= 6-F, R2 = CH3) showed poor activity against EAC 
cell with IC50 between 95.25 and 155.24µg/mL. 
4. CONCLUSION 
Introduction of 5,6-benzo group in the 
coumarin ring is found enhance the in vitro 
cytotoxic activity against DAL cell line. Similarly, 
introduction of isopropyl group at 6-position in 
the coumarin ring is found enhance the in vitro 
cytotoxic activity against EAC cell line. 
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